Plasma total homocysteine concentrations in obese and non-obese female patients with type 2 diabetes mellitus; its relations with plasma oxidative stress and nitric oxide levels

Clinical Hemorheology and Microcirculation

Volumn 33, Issue 1, 2005, Pages 41-46

  Konukoǧlu, Dildar ^a,c   Serin, Özden ^b   Turhan, Mehtap Sultan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Taksim Education and Training Hospital   (Turkey)

^c Fatih Sitesi   (Turkey)

Author keywords

Diabetes; Homocysteine; Hypertension; Lipid peroxidation; Nitric oxide

Indexed keywords

HOMOCYSTEINE; INSULIN; NITRIC OXIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; ARTICLE; BLOOD PRESSURE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIUM LESION; FEMALE; HUMAN; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS;

BLOOD PRESSURE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; FEMALE; HOMOCYSTEINE; HUMANS; INSULIN; LIPID PEROXIDATION; MIDDLE AGED; NITRIC OXIDE; OBESITY; OXIDATIVE STRESS; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 22744436488     PISSN: 13860291     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. J. Selhub and J.W. Miller, The pathogenesis of hyperhomocysteinemia: interruption of coordinate regulation of S-adenosylmethionine of remethylation and transsulfuration of homocysteine, Am. J. Clin. Nutr. 55 (1992), 131-138.
2. M.R. Nehler, L.M. Taylor and J.M. Porter, Homocysteinemia as a risk factor for atherosclerosis: a review, Cardiovasc. Surg. 5 (1997), 559-567.
3. N.J. Wald, H.C. Watt, M.R. Law, D.G. Weir, J. Mcpartlin and J.M. Scott, Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention, Arch. Intern. Med. 158 (1998), 862-867.
4. M.J. Stampfer, M.R. Malinow, W.C. Willett, L.M. Newcomer, B. Upson, D. Ullmann, P.V. Tishler and C.H. Hennekens, A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians, J.A.M.A. 268 (1992), 877-881.
5. A.R. Folsom, F.J. Nieto, P.G. McGovern, M.Y. Tsai, M.R. Malinow, J.H. Eckfeldt, D.L. Hess and C.E. Davis, Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphism, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study, Circulation 98 (1998), 204-210.
6. R.W. Evans, B.J. Shaten, J.D. Hempel, J.A. Cutler and L.H. Kuller, Homocysteine and risk of cardiovascular disease in Multiple Risk Factor Intervention Trial, Arterioscler. Thromb. Vasc. Biol. 17 (1997), 1947-1953.
7. D.W. Jacobsen, Hyperhomocysteinemia and oxidative stress, Arterioscler. Thromb. Vasc. Biol. 20 (2000), 1182-1184.
8. P. Tosukhowong, S. Sangwatanaroj, S. Jatuporn, P. Prapunwattana, A. Saengsiri, S. Rattanapruks, S. Srimahachota, W. Udayachalerm and P. Tangkijvanich, The correlation between markers of oxidative stress and risk factors of coronary artery disease in Thai patients, Clin. Hemorheol. Microcirc. 29 (2003), 321-329.
9. C. Di Massimo, P. Scarpelli and M.G. Tozzi-Ciancarelli, Possible involvement of oxidative stress in exercise-mediated platelet activation, Clin. Hemorheol. Microcirc. 30 (2004), 313-316.
10. R.S. Ajmani, J.L. Fleg, A.A. Demehin, J.G. Wright, F. O'Connor, J.M. Heim, E. Tarien and J.M. Rifkind, Oxidative stress and hemorheological changes induced by acute treadmill exercise, Clin. Hemorheol. Microcirc. 28 (2003), 29-40.
11. J.C. Chambers, A. McGregor, J. Jean-Marie, O.A. Obeid and J.S. Kooner, Demonstration of rapid onset vascular enothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy, Circulation 99 (1999), 1156-1160.
12. J.R. Sowers and M. Epstein, Diabetes mellitus and associated hypertension, vascular disease, and nephropathy, Hypertension 26 (1995), 869-879.
13. A. Andersson, L. Brattstrom, B. Israelsson, A. Isaksson, A. Hamfelt and B. Hultberg, Plasma homocysteine before an after methionine loading with regard to age, gender, and menopausal status, Eur. J. Clin. Invest. 22 (1992), 79-87.
14. World Health Organization Department of Noncommunicable Disease Surveilance, Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: Diagnosis and classifications of diabetes mellitus: report of a WHO consultation, Geneva, World Health Org., 1999.
15. World Health Organization, WHO document. Measuring obesity-classification and description of anthropometric data, Copenhagen, WHO Regional Office for Europe, Nutrition Unit EUR/ICP/NUT 125 (1998).
16. J.A. Buege and S.D. Aust, Microsomal lipid peroxidation, Methods Enzymol. 52 (1978), 302-310.
17. E.K. Hoogeveen, P.J. Kostense, P.J. Beks, A.J. Mackaay, C. Jakobs, L.M. Bouter, R.J. Heine and C.D. Stehouwer, Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study, Arterioscler. Thromb. Vasc. Biol. 18 (1998), 133-138.
18. S. Das, T. Reynolds, A. Patnaik, N. Rais, L.M. Fink and V.A. Fonseca, Plasma homocysteine concentrations in type II diabetic patients in India: Relationship to body weight, J. Diabetes Complications 13 (1999), 200-203.
19. M. Buysschaert, A.S. Dramais, P.E. Wallemacq and M.P. Hermans, Hyperhomocysteinemia in type 2 diabetes. Relationship to macroangiopathy, nephropathy, and insulin resistance, Diabetes Care 23 (2000), 1816-1822.
20. M. Al-Nozah, N. Al-Daghri, W.A. Bartlett, O. Al-Attas, M. Al-Maatouq, S.C. Martin, S. Kumar and A.F. Jones, Serum homocysteine concentration is related to diabetes mellitus, but not to coronary heart disease, in Saudi Arabians, Diabetes Obes. Metab. 4 (2002), 118-123.
21. G. Marchesini, R. Manini, G. Bianchi, S. Sassi, S. Natale, S. Chierici, F. Visani, L. Baraldi, G. Forlani and N. Melchionda, Homocysteine and psychological traits: a study in obesity, Nutrition 18 (2002), 403-407.
22. A. Passaro, K. D'Elia, P.L. Pareschi, F. Calzoni, M. Carantoni, R. Fellin and A. Solini, Factors influencing plasma homocysteine concentrations in type 2 diabetes, Diabetes Care 23 (2000), 420-421.
23. D.W. Jacobsen, Hyperhomocysteinemia and oxidative stress, Arterioscler. Thromb. Vasc. Biol. 20 (2000), 1182-1184.
24. L. Brattstrom, and D.E. Wilcken, Homocysteine and cardiovascular disease: cause or effect, Am. J. Clin. Nutr. 72 (2000), 315-325.
25. P.M. Kanani, C.A. Sinkey, R.L. Browning, M. Allaman, H.R. Knapp and W.G. Haynes, Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocysteinemia in humans, Circulation 100 (1999), 1161-1168.
26. H. Li and U. Forstermann, Nitric oxide in pathogenesis of vascular disease, J. Pathol. 190 (2000), 224-254.
27. J.Y. Jeremy, A.P. Yim, S. Wan and G.D. Angelini, Oxidative stress, nitric oxide, and vascular disease, J. Card. Surg. 17 (2002), 324-327.
28. V. Schachinger, M.B. Britten, M. Elsner, D.H. Walter, I. Scharrer and A.M. Zeiher, A positive family history of premature coronary artery disease is associated with impaired endothelium-dependent coronary blood flow regulation, Circulation 99 (1999), 1156-1160.
29. R.H. Boger, S.M. Bode-Boger and J.C. Frolich, The arginine-nitric oxide pathway: role in atherosclerosis and therapeutic implications, Atherosclerosis 127 (1996), 1-11.
30. J.F. Brun, I. Aloulou and E. Varlet-Marie, Hemorheological aspects of the metabolic syndrome: markers of insulin resistance, obesity or hyperinsulinemia?, Clin. Hemorheol. Microcirc. 30 (2004), 203-209.
31. N. Babu and M. Singh, Influence of hyperglycemia on aggregation, deformability and shape parameters of erythrocytes, Clin. Hemorheol. Microcirc. 31 (2004), 273-280.
32. G. Caimi, R. LoPresti, M. Montana, C. Carollo, G. Amodeo, A. Romano and B. Canino, Polymorphonuclear leukocyte: rheology, metabolism and integral pattern in vascular atherosclerotic disease and in type 2 diabetes mellitus, Clin. Hemorheol. Microcirc. 30 (2004), 229-235.